Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2010 by Hospital Carlos III, Madrid.
Recruitment status was:  Recruiting
Information provided by:
Hospital Carlos III, Madrid Identifier:
First received: February 9, 2010
Last updated: June 24, 2010
Last verified: February 2010

The advent of new antiretroviral drugs improved the management of HIV naive patients in terms of efficacy. However, the long term metabolic profile of this drugs has not yet been compared and associations between new antiretrovirals and cardiovascular events remains controversial.

Moreover, the better tolerability and easy dosage of this new drugs might hypothetically influence adherence and QOL of HIV patients.

Cardiovascular Disease
HIV Infections

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Metabolic Profile and Cardiovascular Biomarker Pattern Compared in naíve Patients Initiating HAART With TDF-FTC and Raltegravir 400mg BID Vs Darunavir 800 mg Plus Ritonavir 100 mg QD; a One Year Follow-up Observational Study

Resource links provided by NLM:

Further study details as provided by Hospital Carlos III, Madrid:

Primary Outcome Measures:
  • lipid profile defined as a clinically significant increment (delta) in Total cholesterol LDL, HDL y non-LDL cholesterol. [ Time Frame: baseline and week 12, 24, 36 and 48 ]
  • Insulin resistance defined by HOMA index. [ Time Frame: baseline and week 12, 24, 36 and 48 ]
  • Cardiovascular biomarkers: ICAM, VICAM, IL-6, PCR hs... [ Time Frame: baseline and week 12, 24, 36 and 48 ]

Secondary Outcome Measures:
  • Antiretroviral adherence and quality of life items. [ Time Frame: baseline and week 12,24,36,48 ]
  • Efficacy defined as viral suppression and CD4 count recovery [ Time Frame: baseline and week 12,24,36,48 ]

Estimated Enrollment: 120
Study Start Date: February 2010
Estimated Study Completion Date: January 2011
Estimated Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Raltegravir Cohort
Patients taking RAL 400 mg BID with Truvada
Darunavir Cohort
Patients taking Darunavir 800 mg QD plus Norvir 100 mg QD with truvada


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Consecutive naïve patients regularly attended at a referral outclinic. 1:1 Randomization in two arms by a local electronic process.

Inclusion Criteria:

  • VIH-1

Exclusion Criteria:

  • pregnancy
  • previous Antiretroviral exposure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01066065

Contact: Jose Medrano, MD +34914532531

Hospital Carlos III Recruiting
Madrid, Spain, 28029
Sponsors and Collaborators
Hospital Carlos III, Madrid
  More Information

Responsible Party: Hospital Carlos III, Vicente Soriano Identifier: NCT01066065     History of Changes
Other Study ID Numbers: HCIII0110
Study First Received: February 9, 2010
Last Updated: June 24, 2010

Keywords provided by Hospital Carlos III, Madrid:
cardiovascular disease
metabolic disorder
HIV naive patients initiating HAART with Raltegravir or boosted Darunavir

Additional relevant MeSH terms:
HIV Infections
Cardiovascular Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Raltegravir Potassium
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
HIV Integrase Inhibitors
Integrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
HIV Protease Inhibitors
Protease Inhibitors processed this record on April 25, 2017